433
Participants
Start Date
January 31, 2010
Primary Completion Date
March 31, 2012
Study Completion Date
March 31, 2012
Armodafinil
Doses of either 150mg/day or 200 mg/day in tablet form taken orally, once daily in the morning.
Placebo
Matching Placebo, also in tablet form taken orally, once daily in the morning.
Birmingham Research Group, Birmingham
Southwestern Research, Beverly Hills
Collaborative NeuroScience Network, Garden Grove
Sun Valley Behavioral Medical, Imperial
University of California Irvine, Irvine
Excell Research, Oceanside
Artemis Institute for Clinical Research, San Diego
Clinical Innovations Inc., Santa Ana
Viking Clinical Research Center, Temecula
CNS Clinical Research Group - Florida Clinical Research Cent, Coral Springs
Gulfcoast Clinical Research Center, Fort Myers
Sarkis Clinical Trials, Gainesville
Dr. Vijapura and Assoc., Jacksonville
Fidelity Clinical Research, Lauderhill
Clinical Neuroscience Solutions, Inc., Orlando
University of South Florida, Tampa
Comprehensive Neuroscience, Inc, Atlanta
Northwest Behavioral Research Center, Roswell
AMR Baber Research Inc., Naperville
American Medical Research, Oak Brook
CNS - Comprehensive Neuro Science, Park Ridge
Pharmasite Research, Inc, Baltimore
AccelRx Research, Fall River
Mid-America Clinical Research, LLC, St Louis
CRI Worldwide, LLC, Mount Laurel
Albequerque Neuroscience, Albuquerque
Social Psychiatry Research Institute, Brooklyn
Eastside Comprehensive Medical Center, New York
Finger Lakes Clinical Research, Rochester
Richmond Behavioral Associates, Staten Island
Richard Weisler, MD and Associates, Raleigh
Charak Clinical Research Center, Beachwood
Midwest Clinical Research Center, Dayton
Oregon Center for Clinical Investigations, Inc, Salem
Suburban Research Associates, Media
Scranton Counseling Center, Scranton
Carolina Clinical Trials, Inc., Charleston
Community Clinical Research, Austin
FutureSearch Trials of Neurology, Austin
Northwest Clinical Research Center, Bellevue
Lead Sponsor
Cephalon
INDUSTRY